Ophthalmic Industry Veteran Scott Hunter Passes Away

Longtime ophthalmic industry leader Scott Hunter passed away on December 3, Neurotech announced. Mr. Hunter was the Chief Commercial Officer of Neurotech, a position he held since January 2023.

“The entire Neurotech family mourns this loss. On behalf of the Board of Directors, management team and employees, we extend our deepest sympathies to Scott’s family,” Neurotech stated in a news release.  “Scott joined Neurotech in January of 2023, and brought his remarkable passion, experience, and energy to the company. He was an exceptional partner and instrumental in building the commercial strategy and infrastructure. Scott loved his family, friends, sports and spent more than two decades in eye care working in rare disease and specialty markets. He will be deeply missed.”

Mr. Hunter had more than two decades of eye care experience. Before serving a Neurotech’s first Chief Commercial Officer, he worked at Novartis where he was the Global Marketing Head for Luxturna (voretigene neparvovec-rzyl), responsible for advancing the global strategy for the first commercially approved ocular gene therapy. Before Novartis, Mr. Hunter was at Shire, where he was instrumental in the build-out of the US ophthalmics franchise and launch of Xiidra, culminating in the divestiture to Novartis for up to $5.3 billion. Prior to that, he spent 12 years at Bausch & Lomb, where he held roles of increasing responsibility across research and development (R&D) and marketing.

He earned his M.S. in Pharmacoeconomics from the University of Florida, and his MBA from the University of Tampa after completing his B.S. in Biology at the University of South Florida.